Travere Therapeutics, Inc. TVTX Q3 2025 earnings
Reported October 30, 2025 · After market close
Revenue$164.9MBeat by $17.9M
EPS$0.28Beat by $0.59
Revenue estimate$147.0M
EPS estimate-$0.31
Next report
Aug 5, 2026 (In 1 week)Revenue estimate$159.2M
EPS estimate-$0.14
Financials
Q3 2025Valuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
Ask the moment Travere Therapeutics, Inc. reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI
Claude
Questions, answered.
- When did Travere Therapeutics, Inc. report Q3 2025 earnings?
- Travere Therapeutics, Inc. (TVTX) reported Q3 2025 earnings on October 30, 2025 after market close.
- What were Travere Therapeutics, Inc.'s Q3 2025 revenue and EPS?
- Travere Therapeutics, Inc. reported revenue of $164.9M and eps of $0.28 for Q3 2025.
- Did Travere Therapeutics, Inc. beat estimates in Q3 2025?
- Revenue beat the consensus estimate of $147.0M by $17.9M. EPS beat the consensus estimate of $-0.31 by $0.59.
- How did Travere Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 162.1% from $62.9M a year earlier.
- Where can I find Travere Therapeutics, Inc.'s Q3 2025 SEC filings?
- You can read the 10-Q periodic report (0001438533-25-000056) directly on SEC EDGAR. The filing index links above go to sec.gov.